M
Mignon L. Loh
Researcher at University of California, San Francisco
Publications - 472
Citations - 42124
Mignon L. Loh is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Leukemia & Medicine. The author has an hindex of 82, co-authored 407 publications receiving 35918 citations. Previous affiliations of Mignon L. Loh include Children's Oncology Group & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia.
Lauren K. Meyer,Cristina Delgado-Martin,Ritu Roy,Benjamin J. Huang,Tiffaney Vincent,Adam B. Olshen,Brent L. Wood,Yu Liu,Jinghui Zhang,Charles G. Mullighan,Terzah M. Horton,Mignon L. Loh,Meenakshi Devidas,Elizabeth A. Raetz,Robert J. Hayashi,Stuart Winter,Kimberly P. Dunsmore,Stephen P. Hunger,David T. Teachey,Michelle L. Hermiston +19 more
TL;DR: This work hypothesizes that T-cell acute lymphoblastic leukemia is a genetically heterogeneous disease, which has largely precluded the use of genetic mutations for risk stratification, and that these mutations should be controlled for in patients diagnosed with T-ALL.
Journal ArticleDOI
A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1.
Laura B. Ramsey,John C. Panetta,Colton Smith,Wenjian Yang,Yiping Fan,Naomi J. Winick,Paul L. Martin,Cheng Cheng,Meenakshi Devidas,Ching-Hon Pui,William E. Evans,Stephen P. Hunger,Mignon L. Loh,Mary V. Relling +13 more
TL;DR: A genome-wide analysis showed that methotrexate clearance was associated with polymorphisms in SLCO1B1 (p = 2.1 × 10 −11), a gene that encodes for an organic anion transporter that is known to transport methot Rexate.
Journal ArticleDOI
Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement
Simon Bomken,Amir Enshaei,Edward C. Schwalbe,Aneta Mikulasova,Yun Feng Dai,Masood Zaka,Kent Fung,Matthew Bashton,Huezin H Lim,Lisa Jones,Nefeli Karataraki,Emily Winterman,Cody Ashby,Andishe Attarbaschi,Yves Bertrand,Jutte Bradtke,Barbara Buldini,G. A. Amos Burke,Giovanni Cazzaniga,G. Gohring,Hesta A De Groot-Kruseman,Claudia Haferlach,Luca Lo Nigro,Mayur Parihar,Adriana Plesa,E. Seaford,Edwin Sonneveld,Sabine Strehl,V H J van der Velden,Vikki Rand,Stephen P. Hunger,Christine J. Harrison,Chris M. Bacon,Frederik W. van Delft,Mignon L. Loh,John Moppett,Josef Vormoor,Brian A Walker,Anthony V. Moorman,Lisa J. Russell +39 more
TL;DR: To develop effective management strategies this patient group must be allowed access to contemporary, minimal residual disease adapted, prospective clinical trial protocols.
Journal ArticleDOI
Amplification of AML1 Does Not Impact Early Outcome of Children with Acute Lymphoblastic Leukemia (ALL) Treated with Risk-Directed Chemotherapy: A Report From the Children's Oncology Group (COG).
Nyla A. Heerema,Andrew J. Carroll,Michael J. Borowitz,Meenakshi Devidas,Eric C. Larson,Mignon L. Loh,Leonard A. Mattano,Kelly W. Maloney,Elizabeth A. Raetz,Brent L. Wood,Naomi J. Winick,Stephen P. Hunger,William L. Carroll +12 more
TL;DR: Early response to risk-adapted therapy is similar in children with and without amp( AML 1), and the distribution of NCI risk group distribution, 2-year event-free survival (EFS), and overall survival (OS) were similar between patients with andWithout amp(AML1).
Proceedings ArticleDOI
Abstract 4369: Rearrangements of the erythropoietin receptor are recurrent in Ph-like acute lymphoblastic leukemia and are sensitive to Jak2 inhibition
Ilaria Iacobucci,Kathryn G. Roberts,Yongjin Li,Jinghui Zhang,Richard C. Harvey,Debbie Payne-Turner,Marcus B. Valentine,Kelly McCastlain,John Easton,I-Ming Chen,Michael Rusch,Steven M. Kornblau,Marina Konopleva,Elisabeth Paietta,Jacob M. Rowe,Ching-Hon Pui,Julie M. Gastier-Foster,Shalini C. Reshmi,Mignon L. Loh,Cheryl L. Willman,James R. Downing,Stephen P. Hunger,Charles G. Mullighan +22 more
TL;DR: Iacobucci et al. as discussed by the authors used whole transcriptome sequencing, real-time quantitative PCR (qPCR) and Sanger sequencing to detect and map the rearrangements of the erythropoietin receptor (EPOR) in 307 Ph-like ALL.